InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,419.20
(
0.00%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.46
(
0.40%
)
Bitcoin
64,262.29
(
0.41%
)
Post# of 251721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: semi_infinite post# 236373

Monday, 03/01/2021 4:40:26 PM

Monday, March 01, 2021 4:40:26 PM

Post# of 251721
FGEN -18%/AH on_news_of_to-be-scheduled_adcomm_ for Roxadustat US NDA:

https://www.globenewswire.com/news-release/2021/03/01/2184662/0/en/FibroGen-Provides-Regulatory-Update-on-Roxadustat.html

FibroGen, Inc. and its partner, AstraZeneca today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will hold an advisory committee (AdCom) meeting to review the new drug application for roxadustat in the U.S. The companies have not received a confirmed AdCom meeting date from the FDA.

FGEN also reported 4Q20 financials (https://www.globenewswire.com/news-release/2021/03/01/2184671/0/en/FibroGen-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html ).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up